Conference Reports for NATAP

The International Liver Congress™ EASL - European Association for the Study of the Liver 2019 April 10-14 Vienna Austria Back

RO7049389, a core protein allosteric modulator, demonstrates robust decline in HBV DNA and HBV RNA in chronic HBV infected patients       EASL 2018 RO7049389, a core protein allosteric modulator, demonstrates robust anti-HBV activity in chronic hepatitis B patients and is safe and well tolerated - (04/18/18)   Combination treatment of a TLR7 agonist RO7020531 and a core protein allosteric modulator RO7049389 achieved sustainable viral load suppression and HBsAgloss in an AAV-HBV mouse model - (04/18/18)   EASL 2019 Reported by Jules Levin   HBV at EASL